-
PENELOPE (JBCRG-21)
GLOBAL This trial is a collaborative study with GBG.
Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy“PENELOPEB”
- Status
- No Longer Recruiting
- Objectives
- To compare invasive disease free survival (iDFS) for albociclib vs. placebo in patients with residual invasive breast cancer and high CPS-EG score - after neoadjuvant chemotherapy receiving standard adjuvant endocrine therapy for HR- positive/HER2-normal primary breast cancer.
- Subjects
- Endpoints
- Invasive disease free survival (iDFS)
- Trial Period
- Lead Principal Investigator
- Target Sample Size
- 45
- Regimen
- palbociclib 125 mg vs Placebo
- Source of Funding
- GBG Forschungs GmbH
- Conference Presentation
- Articles and Publications
- Memo
- COI Disclosure